Launch of the Da Vinci Xi Robotic System is the highlight of the Robotic Colorectal Cancer Symposium organized with the Association of Colon and Rectal Surgeons of India
Pfizer’s total cumulative revenue from Seagen therapies is expected to reach $36 billion by 2028, according to GlobalData, a leading data and analytics company.
Twelve hospitals across India will be part of the network which will support the trial in India
Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year
This clinical study aims to evaluate the efficacy of JAB-21822 in combination with cetuximab in patients with KRAS G12C-mutated colorectal cancer.
On the precision oncology front, expanded larotrectinib data will focus on efficacy and safety findings for pediatric and adult patients with NTRK gene fusion-positive solid tumors
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
The technology was able to identify approximately 32 percent more adenomas than standard colonoscopy procedures
It is the first hospital in the country to achieve the significant milestone of completing over 2600 robotic surgeries for treating patients with prostate, kidney and urinary bladder cancer
Subscribe To Our Newsletter & Stay Updated
